Nyxoah SA の最大収益セグメントは Innovative Solutions で、最新の利益発表における収益は 10,020,000 です。地域別に見ると、Germany が Nyxoah SA の主要市場であり、収益は 4,488,000 です。
Nyxoah SAは収益を上げていますか?
いいえ、最新の財務諸表によると、Nyxoah SAの純損失は$0です。
Nyxoah SAに負債はありますか?
いいえ、Nyxoah SAの負債は0です。
Nyxoah SAの発行済株式数は何株ですか?
Nyxoah SAの総発行済株式数は0株です。
主要データ
前終値
$1.31
始値
$1.37
当日レンジ
$1.37 - $1.47
52週レンジ
$1.26 - $8.58
取引高
82.8K
平均取引高
323.0K
配当利回り
--
1株当たり利益(TTM)
-2.31
時価総額
$147.1M
Nyxoah SAとは何ですか?
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 154 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.